title: [Coincidence of adenocarcinoma and MALT lymphoma of the prostate--first report].
abstract: BACKGROUND
  First description of a prostate adenocarcinoma coinciding with the rare MALT lymphoma of the prostate.
  
  
  METHODS
  68-year-old patient with a pT2c, pN0, M0, Gleason 3 + 3 prostate carcinoma (retropubic radical prostatectomy with pelvic lymphadenectomy) and systemic indolent MALT lymphoma of the prostate (bone marrow biopsy). Therapy and course are described and further explained by referring to case reports found in the literature. In this context, possible pathogenetic mechanisms, the prognosis for this special disease and possible therapeutic approaches are discussed.
  
  
  CONCLUSIONS
  MALT lymphomas of the prostate are rare, and so far a coincidence with a prostate carcinoma is unprecedented. The prostate carcinoma is treated according to stage, while the MALT lymphoma is managed according to individual treatment strategies. The histopathological classification is more important for the prognosis. Treatment with antibiotics to eradicate possible copathogenic Helicobacter pylori is discussed as an innovative therapeutic approach. The pathogenesis of the MALT lymphoma of the prostate cannot yet be clarified definitively according to a literature review.
authors.affiliation: Klinik für Urologie, Bundeswehrkrankenhaus Hamburg. Daniela.Uthoff@gmx.de
authors.forename: D
authors.initials: D
authors.lastname: Uthoff
authors.forename: S
authors.initials: S
authors.lastname: Schmidt
authors.forename: C
authors.initials: C
authors.lastname: Matthies
authors.forename: M
authors.initials: M
authors.lastname: Tiemann
authors.forename: W
authors.initials: W
authors.lastname: Wagner
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D019046:Bone Marrow Neoplasms / Q000473:pathology / Q000556:secondary; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D008297:Male; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*